Цидувектамиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2412587-62-1

immunoglobulin G4-kappa/lambda2, anti-[Homo sapiens TMEFF2 (transmembrane protein with EGF like and two follistatin like domains 2, cancer/testis antigen family 120 member 2, CT120.2, tomoréguline)] and anti-[Homo sapiens CD3E (CD3e, CD3 epsilon)], monoclonal antibody, bispecific;
gamma4 heavy chain anti-TMEFF2 (1-445) [VH anti-TMEFF2 (Homo sapiens IGHV3-23*01 (94.9%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2, nG4m(a) CH2 L92 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 F1.3>A (232), L1.2>A (233), L92 (307) (229-338), CH3 (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain anti-TMEFF2 1'-214') [V-KAPPA anti-TMEFF2 (Homo sapiens IGKV1-6*01 (100%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-117') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')];
gamma4 heavy chain anti-CD3E (1''-447'') [VH anti-CD3E (Homo sapiens IGHV6-1*01 (88.1%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [10.9.10] (26-35.53-61.100-109)) (1''-120'') -Homo sapiens IGHG4*01, G4v5 h P10, G4v4 CH2 A1.3, A1.2, nG4m(a) CH2 L92 (CH1 (121''-218''), hinge 1-12 S10>P (228) (219''-230''), CH2 F1.3>A (234), L1.2>A (235), L92 (309) (231''-340''), CH3 F85.1>L (405), R88>K (409) (341''-445''), CHS (446''-447'')) (121''-447'')], (134''-215''')-disulfide with lambda2 light chain anti-CD3E (1'''-216''') [V-LAMBDA anti-CD3E (Homo sapiens IGLV2-23*02 (84.8%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.10] (26-34.52-54.91-100)) (1'''-110''') -Homo sapiens IGLC2*01 (100%) (111'''-216''')]; dimer (224-226'':227-229'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей